The University of Chicago Header Logo

Connection

Gregory Karczmar to Contrast Media

Back to Details
This is a "connection" page, showing publications Gregory Karczmar has written about Contrast Media.
Gregory Karczmar
Connection Strength
10.541
Contrast Media
  1. Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. Magn Reson Imaging. 2023 Dec; 104:9-15.
    View in: PubMed
    Score: 0.615
  2. Signal intensity form of the Tofts model for quantitative analysis of prostate dynamic contrast enhanced MRI data. Phys Med Biol. 2021 01 22; 66(2):025002.
    View in: PubMed
    Score: 0.515
  3. Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent. Phys Med. 2021 Jan; 81:31-39.
    View in: PubMed
    Score: 0.512
  4. Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI. Tomography. 2019 06; 5(2):260-265.
    View in: PubMed
    Score: 0.459
  5. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615.
    View in: PubMed
    Score: 0.438
  6. Comparison of arterial input functions measured from ultra-fast dynamic contrast enhanced MRI and dynamic contrast enhanced computed tomography in prostate cancer patients. Phys Med Biol. 2018 01 30; 63(3):03NT01.
    View in: PubMed
    Score: 0.419
  7. Dynamic field-of-view imaging to increase temporal resolution in the early phase of contrast media uptake in breast DCE-MRI: A feasibility study. Med Phys. 2018 Mar; 45(3):1050-1058.
    View in: PubMed
    Score: 0.418
  8. MRI ductography of contrast agent distribution and leakage in normal mouse mammary ducts and ducts with in situ cancer. Magn Reson Imaging. 2017 07; 40:48-52.
    View in: PubMed
    Score: 0.395
  9. Ultrafast Bilateral DCE-MRI of the Breast with Conventional Fourier Sampling: Preliminary Evaluation of Semi-quantitative Analysis. Acad Radiol. 2016 09; 23(9):1137-44.
    View in: PubMed
    Score: 0.373
  10. X-ray fluorescence microscopy demonstrates preferential accumulation of a vanadium-based magnetic resonance imaging contrast agent in murine colonic tumors. Mol Imaging. 2015; 14.
    View in: PubMed
    Score: 0.338
  11. High resolution 3D MRI of mouse mammary glands with intra-ductal injection of contrast media. Magn Reson Imaging. 2015 Jan; 33(1):161-5.
    View in: PubMed
    Score: 0.330
  12. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
    View in: PubMed
    Score: 0.292
  13. Use of a reference tissue and blood vessel to measure the arterial input function in DCEMRI. Magn Reson Med. 2010 Dec; 64(6):1821-6.
    View in: PubMed
    Score: 0.255
  14. Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology. 2009 Nov; 253(2):399-406.
    View in: PubMed
    Score: 0.236
  15. A new approach to analysis of the impulse response function (IRF) in dynamic contrast-enhanced MRI (DCEMRI): a simulation study. Magn Reson Med. 2009 Jul; 62(1):229-39.
    View in: PubMed
    Score: 0.231
  16. Quantitative analysis of water proton spectral lineshape: a novel source of contrast in MRI. Phys Med Biol. 2008 Sep 07; 53(17):4509-22.
    View in: PubMed
    Score: 0.217
  17. MRI of perfluorocarbon emulsion kinetics in rodent mammary tumours. Phys Med Biol. 2006 Jan 21; 51(2):211-20.
    View in: PubMed
    Score: 0.181
  18. New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med. 2004 Mar; 51(3):487-94.
    View in: PubMed
    Score: 0.160
  19. Parametric maps of spatial two-tissue compartment model for prostate dynamic contrast enhanced MRI - comparison with the standard tofts model in the diagnosis of prostate cancer. Phys Eng Sci Med. 2023 Sep; 46(3):1215-1226.
    View in: PubMed
    Score: 0.153
  20. Pharmacokinetic Analysis of Enhancement-Constrained Acceleration (ECA) reconstruction-based high temporal resolution breast DCE-MRI. PLoS One. 2023; 18(6):e0286123.
    View in: PubMed
    Score: 0.152
  21. Safely reducing unnecessary benign breast biopsies by applying non-mass and DWI directional variance filters to ADC thresholding. BMC Med Imaging. 2022 09 29; 22(1):171.
    View in: PubMed
    Score: 0.145
  22. Spectrally inhomogeneous effects of contrast agents in breast lesion detected by high spectral and spatial resolution MRI. Acad Radiol. 2002 Aug; 9 Suppl 2:S352-4.
    View in: PubMed
    Score: 0.143
  23. Functional and anatomic imaging of tumor vasculature: high-resolution MR spectroscopic imaging combined with a superparamagnetic contrast agent. Acad Radiol. 2002 May; 9 Suppl 1:S115-8.
    View in: PubMed
    Score: 0.140
  24. Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
    View in: PubMed
    Score: 0.140
  25. Enhancement-constrained acceleration: A robust reconstruction framework in breast DCE-MRI. PLoS One. 2021; 16(10):e0258621.
    View in: PubMed
    Score: 0.136
  26. Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer. Acad Radiol. 2022 06; 29(6):796-803.
    View in: PubMed
    Score: 0.135
  27. An in silico validation framework for quantitative DCE-MRI techniques based on a dynamic digital phantom. Med Image Anal. 2021 10; 73:102186.
    View in: PubMed
    Score: 0.133
  28. Uptake of a superparamagnetic contrast agent imaged by MR with high spectral and spatial resolution. Magn Reson Med. 2000 May; 43(5):633-9.
    View in: PubMed
    Score: 0.122
  29. Low-dose imaging technique (LITE) MRI: initial experience in breast imaging. Br J Radiol. 2019 Nov; 92(1103):20190302.
    View in: PubMed
    Score: 0.116
  30. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356.
    View in: PubMed
    Score: 0.111
  31. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density. Acad Radiol. 2019 07; 26(7):e141-e149.
    View in: PubMed
    Score: 0.110
  32. Comparison of region-of-interest-averaged and pixel-averaged analysis of DCE-MRI data based on simulations and pre-clinical experiments. Phys Med Biol. 2017 Sep 05; 62(18):N445-N459.
    View in: PubMed
    Score: 0.102
  33. In vivo imaging of extraction fraction of low molecular weight MR contrast agents and perfusion rate in rodent tumors. Magn Reson Med. 1997 Aug; 38(2):259-68.
    View in: PubMed
    Score: 0.101
  34. Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. J Magn Reson Imaging. 2017 11; 46(5):1341-1348.
    View in: PubMed
    Score: 0.098
  35. Kinetic Analysis of Benign and Malignant Breast Lesions With Ultrafast Dynamic Contrast-Enhanced MRI: Comparison With Standard Kinetic Assessment. AJR Am J Roentgenol. 2016 Nov; 207(5):1159-1166.
    View in: PubMed
    Score: 0.095
  36. Dynamic contrast measurements in rodent model tumors. Acad Radiol. 1996 Aug; 3 Suppl 2:S384-6.
    View in: PubMed
    Score: 0.094
  37. Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues. Magn Reson Imaging. 2016 Feb; 34(2):197-203.
    View in: PubMed
    Score: 0.090
  38. IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model. AJR Am J Roentgenol. 2015 Sep; 205(3):W313-9.
    View in: PubMed
    Score: 0.089
  39. Comparison of dynamic contrast-enhanced MRI parameters of breast lesions at 1.5 and 3.0?T: a pilot study. Br J Radiol. 2015 May; 88(1049):20150021.
    View in: PubMed
    Score: 0.086
  40. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. Technol Cancer Res Treat. 2013 Feb; 12(1):71-8.
    View in: PubMed
    Score: 0.072
  41. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol. 2012 Jul; 22(7):1451-64.
    View in: PubMed
    Score: 0.070
  42. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
    View in: PubMed
    Score: 0.067
  43. The diverse pathology and kinetics of mass, nonmass, and focus enhancement on MR imaging of the breast. J Magn Reson Imaging. 2011 Jun; 33(6):1382-9.
    View in: PubMed
    Score: 0.066
  44. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol. 2010 Oct 07; 55(19):N473-85.
    View in: PubMed
    Score: 0.063
  45. The use of a reference tissue arterial input function with low-temporal-resolution DCE-MRI data. Phys Med Biol. 2010 Aug 21; 55(16):4871-83.
    View in: PubMed
    Score: 0.062
  46. Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. Magn Reson Med. 2010 Jun; 63(6):1601-9.
    View in: PubMed
    Score: 0.062
  47. Relating dose of contrast media administered to uptake and washout of malignant lesions on DCEMRI of the breast. Acad Radiol. 2010 Jan; 17(1):24-30.
    View in: PubMed
    Score: 0.060
  48. Kinetic curves of malignant lesions are not consistent across MRI systems: need for improved standardization of breast dynamic contrast-enhanced MRI acquisition. AJR Am J Roentgenol. 2009 Sep; 193(3):832-9.
    View in: PubMed
    Score: 0.058
  49. Can DCEMRI assess the effect of green tea on the angiogenic properties of rodent prostate tumors? Phys Med. 2010 Apr; 26(2):111-6.
    View in: PubMed
    Score: 0.058
  50. New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer. J Biol Inorg Chem. 2009 Nov; 14(8):1187-97.
    View in: PubMed
    Score: 0.058
  51. Sensitivity to tumor microvasculature without contrast agents in high spectral and spatial resolution MR images. Magn Reson Med. 2009 Feb; 61(2):291-8.
    View in: PubMed
    Score: 0.056
  52. Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med. 2007 Dec; 58(6):1266-75.
    View in: PubMed
    Score: 0.052
  53. Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging. 2007 Jun; 25(5):593-603.
    View in: PubMed
    Score: 0.048
  54. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
    View in: PubMed
    Score: 0.045
  55. Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med. 2004 Nov; 52(5):1110-7.
    View in: PubMed
    Score: 0.042
  56. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
    View in: PubMed
    Score: 0.041
  57. The effect of varying spectral resolution on the quality of high spectral and spatial resolution magnetic resonance images of the breast. J Magn Reson Imaging. 2003 Oct; 18(4):442-8.
    View in: PubMed
    Score: 0.039
  58. Breast MR imaging with high spectral and spatial resolutions: preliminary experience. Radiology. 2002 Aug; 224(2):577-85.
    View in: PubMed
    Score: 0.036
  59. Robustness of radiomic features of benign breast lesions and hormone receptor positive/HER2-negative cancers across DCE-MR magnet strengths. Magn Reson Imaging. 2021 10; 82:111-121.
    View in: PubMed
    Score: 0.033
  60. Differentiation of nonmetastatic and metastatic rodent prostate tumors with high spectral and spatial resolution MRI. Magn Reson Med. 2001 Jun; 45(6):1046-55.
    View in: PubMed
    Score: 0.033
  61. Patient-Specific Characterization of Breast Cancer Hemodynamics Using Image-Guided Computational Fluid Dynamics. IEEE Trans Med Imaging. 2020 09; 39(9):2760-2771.
    View in: PubMed
    Score: 0.030
  62. Revisiting quantitative multi-parametric MRI of benign prostatic hyperplasia and its differentiation from transition zone cancer. Abdom Radiol (NY). 2019 06; 44(6):2233-2243.
    View in: PubMed
    Score: 0.029
  63. Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75.
    View in: PubMed
    Score: 0.029
  64. Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate. AJR Am J Roentgenol. 2019 01; 212(1):124-129.
    View in: PubMed
    Score: 0.028
  65. Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med. 2019 03; 81(3):2147-2160.
    View in: PubMed
    Score: 0.028
  66. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380.
    View in: PubMed
    Score: 0.027
  67. A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues. J Magn Reson Imaging. 1998 Sep-Oct; 8(5):1126-34.
    View in: PubMed
    Score: 0.027
  68. Fast Temporal Resolution Dynamic Contrast-Enhanced MRI: Histogram Analysis Versus Visual Analysis for Differentiating Benign and Malignant Breast Lesions. AJR Am J Roentgenol. 2018 10; 211(4):933-939.
    View in: PubMed
    Score: 0.027
  69. Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer. Acad Radiol. 2018 03; 25(3):349-358.
    View in: PubMed
    Score: 0.026
  70. Value of breast MRI for patients with a biopsy showing atypical ductal hyperplasia (ADH). J Magn Reson Imaging. 2017 12; 46(6):1738-1747.
    View in: PubMed
    Score: 0.025
  71. Differentiating between T1 and T2* changes caused by gadopentetate dimeglumine in the kidney by using a double-echo dynamic MR imaging sequence. J Magn Reson Imaging. 1996 Sep-Oct; 6(5):764-8.
    View in: PubMed
    Score: 0.024
  72. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.024
  73. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77.
    View in: PubMed
    Score: 0.020
  74. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
    View in: PubMed
    Score: 0.019
  75. Potential of computer-aided diagnosis of high spectral and spatial resolution (HiSS) MRI in the classification of breast lesions. J Magn Reson Imaging. 2014 Jan; 39(1):59-67.
    View in: PubMed
    Score: 0.019
  76. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.
    View in: PubMed
    Score: 0.019
  77. Do we really need contrast agents? Eur J Radiol. 2012 Sep; 81 Suppl 1:S99-100.
    View in: PubMed
    Score: 0.018
  78. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.
    View in: PubMed
    Score: 0.017
  79. Normal parenchymal enhancement patterns in women undergoing MR screening of the breast. Eur Radiol. 2011 Jul; 21(7):1374-82.
    View in: PubMed
    Score: 0.016
  80. High-resolution magnetic resonance colonography and dynamic contrast-enhanced magnetic resonance imaging in a murine model of colitis. Magn Reson Med. 2010 Apr; 63(4):922-9.
    View in: PubMed
    Score: 0.015
  81. The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data. Magn Reson Med. 2010 Mar; 63(3):811-6.
    View in: PubMed
    Score: 0.015
  82. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.014
  83. Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
    View in: PubMed
    Score: 0.014
  84. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.014
  85. DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and nonmass-like enhancement? Med Phys. 2008 Jul; 35(7):3102-9.
    View in: PubMed
    Score: 0.013
  86. Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study. Magn Reson Med. 2008 Apr; 59(4):747-54.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.